Factors influencing activity of oral anticoagulants. Interactions with drugs and food;Czynniki wpływaja̧ce na działanie doustnych antykoagulantów. Interakcje z lekami i pożywieniem

Polski Merkuriusz Lekarski

Volumn 24, Issue 143, 2008, Pages 458-462

  Sawicka Powierza, Jolanta ^a,b   Rogowska Szadkowska, Dorota ^a   Ołtarzewska, Alicja Małgorzata ^a   Chlabicz, Sławomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UDSK Uniwersytet Medyczny   (Poland)

Author keywords

Education; Interactions with drugs and food; Oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450; WARFARIN;

BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; DRUG RESISTANCE; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; HERB DRUG INTERACTION; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HERB-DRUG INTERACTIONS; HUMANS; POLYMORPHISM, GENETIC; THROMBOEMBOLISM; WARFARIN;

EID: 45749093868     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Aithal G.P., Day C.P., Kesteven P.J. i wsp.: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353(9154), 717-719.
2. Alving B.M., Strickler M.P., Knight R.D. i wsp.: Hereditary warfarin resistance. Investigation of a rare phenomen. Arch. Intern. Med., 1985, 145(3), 499-501.
3. Ansell J., Hirsh J., Poller L. i wsp.: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004,126(3), 204S-233S. Errata: Chest, 2005, 127, 415-416.
4. Ansell J., McDonough M., Harmatz J.S. i wsp.: A randomized, double-blind trial of the interaction between cranberry juice and warfarin. J. Throm. Throbolysis, 2007.[Pub. ahead of print]
5. Bartle W.R.: Grapefruit juice might still be factor in warfarin response. Am. J. Health. Syst. Pharm., 1999, 56(7), 676.
6. Beyth R.J., Quinn L.M., Landefeld C.S.: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med., 1998, 105, 91-99.
7. Chesebro J.H., Fuster V., Elveback L.R. i wsp.: Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am. J. Cardiol., 1983, 51(9), 1537-1541.
8. Dale J., Myhre E., Loew D.: Bleeding during acetysalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am. Heart. J., 1980, 99(6), 746-752.
9. Fijałkowska A., Szawłowski A., Wojtukiewicz M. i wsp.: Profilaktyka i przeciwzakrzepowe leczenie u chirurgicznych pacjentów z nowotworami złośliwymi. Nowotwory. J. of Oncol., 2007, 57(2), 53-59.
10. Geerts W.H., Pineo G.F., Heit J.A. i wsp.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126(3), 3385-4005.
11. Harrington R.A., Becker R.C., Ezekowitz M. i wsp.: Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126(3), 513S-48S.
12. Harris J.E.: Interaction of dietary factors with oral anticoagulants: review and applications. J. Am. Diet. Assoc., 1995, 95(5), 580-584.
13. Heck A.M., DeWitt B.A., Lukes A.L.: Potential interactions between alternative therapies and warfarin. Am. J. Health-Syst. Pharm., 2000, 57(13), 1221-1230.
14. Hirsh J., Dalen J., Anderson D.R. i wsp.: Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest., 2001, 119(1), 8S-21S.
15. Ho C.H., Lin M.W., You J.Y. i wsp.: Variations of prothrombin time and international normalized ratio in patients treated with warfarin. Thromb. Res., 2002, 107(5), 277-280.
16. Izzat M.B., Yim A.P., El-Zufari M.H.: A taste of Chinese medicine! Ann. Thorac. Surg., 1998, 66(3), 941-2.
17. Jiang X., Williams K.M., Liauw W.S. i wsp.: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(5), 592-599.
18. Kuijer P.M., Hutten B.A., Prins M.H. i wsp.: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch. Intern. Med., 1999, 159, 457-460.
19. Lam A.Y., Elmer G.W., Mohutsky M.A.: Possible interaction between warfarin and Lycium barbarum. L. Ann. Pharmacother., 2001, 35(10), 1199-1201.
20. Loebstein R., Yonath H., Peleg D. i wsp. Individual variability in sensitivity to warfarin: nature or nurture. Clin. Pharmacol. Ther., 2001, 70(2), 159-164.
21. Mahe I., Bertrand N., Drouet L. i wsp.: Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica, 2006, 91(12), 1621-1627.
22. Mannucci P.M.: Genetic control of anticoagulation. Lancet, 1999, 353(9154), 688-689.
23. Miller L.G., Hume A., Harris I.M. i wsp.: White paper on herbal products. American College of Clinical Pharmacy. Pharmacotherapym 2000, 20, 877-891.
24. Naranjo C.A., Busto U., Sellers E.M. i wsp.: A method for estimating the probability of adverse drug reactions. Ciln. Pharmacol. Ther., 1981, 30(2), 239-245.
25. Oldenburg J., Quenzel E.M., Harbrecht V. i wsp.: Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticaogulant therapy. Br. J. Haematol., 1997, 98, 240-244.
26. O'Reilly R.A.: Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch. Intern. Med., 1981, 141(4), 458-459.
27. O'Reilly R.A., Trager W.F., Rettie A.E. i wsp.: Interaction of amiodorone with racemic warfarin and its separated enantimorphs in humans. Clin. Pharmacol. Ther., 1987, 42, 290-294.
28. O'Reilly R.A., Sahud M.A., Robinson A.J.: Studies on the interaction of warfarin and clofibrate in man. Thromb. Diath. Haemorrh., 1972, 27, 309-318.
29. O'Reilly R.A., Aggeler P.M., Leong L.S. i wsp.: Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. N. Engl. J. Med., 1983, 308, 1229-1123.
30. Owens J.C., Neely W.B., Owen W.R.: Effect of sodium dextrothyroxine in patients receiving anticoagulants. Ciln. Med., 1962, 69, 2283-2284.
31. Roth G.J., Majerus P.W.: The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J. Clin. Invest., 1975, 56, 624-632.
32. Salem D.N., Stein P.D., Al-Ahmad A. i wsp.: Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126(3), 457S-82S.
33. Sawicka-Powierza J., Ołtarzewska A.M., Chlabicz S.: Wiedza o zasadach bezpiecznego stosowania doustnych antykoagulantów u chorych leczonych przewlekle acenokumarolem. Pol. Mer. Lek., 2007, 22(127), 36-40.
34. Schulman S., Henriksson K.: Interaction of ibuprofen and warfarin on primary haemostasis. Br. J. Rheumatol., 1989, 28(1), 46-49.
35. Singer D.E., Albers G.W., Dalen J.E. i wsp.: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest., 2004, 126(3), 429S-56S.
36. Sullivan D.M., Ford M.A., Boyden T.W.: Grapefruit juice and the response to warfarin. Am. J. Health. Syst. Pharm., 1998, 55(15), 1581-1583.
37. Thijssen H.H., Hamulyak K., Willigers H.: 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics - response relationship. Thromb. Haemost., 1988, 60(1), 35-38.
38. Turpie A.G., Gent M., Laupacis A. i wsp.: Aspirin and warfarin after heart-valve replacement: A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N. Engl. J. Med., 1993, 329(8), 524-529.
39. Weitekamp M.R., Aber R.C.: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA, 1983, 249(1), 69-71.
40. Wilson S.J., Wells P.S., Kovacs M.J. i wsp.: Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ, 2003, 169(40), 293-298.
41. Wittkowsky A.K.: A systematic review and inventory of supplement effects on warfarin and other anticoagulants. Thromb. Res., 2005, 117(1-2), 81-86.
42. Yuan C.S., Wei G., Dey L. i wsp.: Brief communication: American ginseng reduces warfarin's in healthly patients; a randomized controlled trial. Ann. Intern. Med., 2004, 141(1), 23-27.
43. Zawilska K., Brożek J., Jaeschke R. i wsp.: Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Med. Prakt., 2005, 6(supl.).